Adenovirus serotype 26 and serotype 35 filovirus vaccines

Patent metadata

Field	Value
Publication number	US-9701718-B2
Application number	US-201113994532-A
Country	US
Kind code	B2
Filing date	Dec 14, 2011
Priority date	Dec 14, 2010
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.

First claim

What is claimed is:

1. A method of inducing a protective immune response against Ebola in a subject, the method comprising:
administering to the subject, as a priming vaccination, an immunologically effective amount of a recombinant adenovirus vector comprising a polynucleotide encoding a first filovirus antigenic protein, wherein the recombinant adenovirus vector is an rAd26 vector;
followed by administering a boosting vaccination to the subject that includes an adenovirus vector comprising a polynucleotide encoding a second filovirus antigenic protein, wherein the adenovirus vector is an rAd35 vector, so as to induce durable T-cell memory in the subject for the first and second filovirus antigenic proteins and
thus immunizing the subject against Ebola,
wherein each of the first and second filovirus antigenic proteins is a glycoprotein from an Ebola virus; and
wherein, three weeks following the boosting vaccination, the subject has an anti-Ebola glycoprotein EC90 antibody titer of at least 1:32,000.

2. The method according to claim 1 , wherein administration is conducted intramuscularly.

3. The method according to claim 1 , wherein the Ebola virus is of species Zaire.

4. The method according to claim 3 , wherein the first and second filovirus antigenic proteins are encoded by SEQ ID NO: 1.

5. The method according to claim 1 , wherein the Ebola virus is of species Sudan/Gulu.

6. The method according to claim 5 , wherein a filovirus antigenic protein is encoded by SEQ ID NO: 2.

7. The method according to claim 5 , wherein a filovirus antigenic protein is encoded by SEQ ID NO: 3.

8. A method of inducing immune response protective against death due to infection by Ebola in a subject, the method comprising:
administering to the subject, as a priming vaccination, an immunologically effective amount of a recombinant adenovirus vector comprising a polynucleotide encoding a first antigenic protein encoded by a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, and SEQ ID NO:3, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein;
followed by administering a boosting vaccination to the subject, which includes an adenovirus vector comprising a polynucleotide encoding a second antigenic protein encoded by a nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, and SEQ ID NO:3, wherein the adenovirus vector comprises an adenovirus 35 capsid protein.

9. The method according to claim 8 , wherein the first and second antigenic proteins are encoded by SEQ ID NO: 1.

10. A method of inducing an immune response protective against death due to infection by Ebola in a subject, the method comprising:
administering to the subject a priming vaccination comprising an E1/E3-deleted rAd26 vector with an Ad5 E4orf6 sequence, the rAd26 vector comprising a polynucleotide encoding a first filovirus antigenic protein; and then
administering to the subject a boosting vaccination comprising an E1/E3-deleted rAd35 vector with an Ad5 E4orf6 sequence, the rAd35 vector comprising a polynucleotide encoding a second filovirus antigenic protein;
so as to induce durable T-cell memory in the subject for the first and second filovirus antigenic proteins and thus protecting the subject against death due to infection by Ebola,
wherein each of the first and second filovirus antigenic proteins is a glycoprotein from an Ebola virus.

11. The method according to claim 10 , wherein administration is conducted intramuscularly.

12. The method according to claim 10 , wherein the Ebola virus is of species Zaire.

13. The method according to claim 12 , wherein the first and second filovirus antigenic proteins are encoded by SEQ ID NO: 1.

14. A method of inducing a protective immune response against Ebola in a subject, the method comprising:
administering to the subject, as a priming vaccination, an immunologically effective amount of a recombinant adenovirus vector comprising a polynucleotide encoding a first filovirus antigenic protein, wherein the recombinant adenovirus vector is an rAd26 vector;
followed by administering a boosting vaccination to the subject that includes an adenovirus vector comprising a polynucleotide encoding a second filovirus antigenic protein wherein the adenovirus vector is an rAd35 vector,
so as to induce durable T-cell memory in the subject for the first and second filovirus antigenic proteins and thus immunizing the subject against Ebola,
wherein each of the first and second filovirus antigenic proteins is a glycoprotein from an Ebola virus, and
wherein at least one of the priming vaccination or the boosting vaccination comprises an adjuvant selected from the group consisting of QS-21, Detox-PC, MPL-SE, MoGM-CSF, TiterMax-G, CRL- 1005, GERBU, TERamide, PSC97B, Adjumer, PG-026, GSK-I, GcMAF, B-alethine, MPC-026, Adjuvax, CpG ODN, Betafectin, MF59, lectins, growth factors, cytokines and lymphokines, alpha-interferon, gamma interferon, platelet derived growth factor (PDGF), granulocyte-colony stimulating factor (gCSF), granulocyte macrophage colony stimulating factor (gMCSF), tumor necrosis factor (TNF), epidermal growth factor (EGF), IL-I, IL-2, IL-4, IL-6, IL-8, IL-I0, IL-12, and encoding nucleic acids of any thereof.

15. A method of inducing a protective immune response against Ebola in a subject, the method comprising:
administering to the subject a priming vaccination, the priming vaccination comprising:
an immunologically effective amount of a first recombinant adenovirus vector comprising a polynucleotide encoding a first filovirus antigenic protein, and
a immunologically effective amount of a second recombinant adenovirus vector comprising a polynucleotide encoding a second filovirus antigen protein;
wherein the first and second recombinant adenovirus vectors are rAd26 vectors;

followed by administering a boosting vaccination to the subject, the boosting vaccination comprising:
an immunologically effective amount of a third adenovirus vector comprising a polynucleotide encoding the first filovirus antigenic protein, and
a immunologically effective amount of a fourth recombinant adenovirus vector comprsing a polynucleotide encoding the second filovirus antigen protein
wherein the third and fourth adenovirus vectors are rAd35 vectors,

so as to induce durable T-cell memory in the subject for the first and second filovirus antigenic proteins and thus immunizing the subject against Ebola,
wherein the first and second filovirus antigenic proteins are glycoproteins from different species of Ebola virus.

Assignees

• Sullivan Nancy J
• Nabel Gary J
• Asiedu Clement
• Cheng Cheng
• Pau Maria Grazia
• Goudsmit Jaap
• Janssen Vaccines & Prevention Bv
• The Us Secretary Dept Of Health And Human Services The Office Of Tech Transfer Nat Inst Of Health

Inventors

• Sullivan Nancy J
• Nabel Gary J
• Asiedu Clement
• Cheng Cheng
• Pau Maria Grazia
• Goudsmit Jaap

Classifications

• C12N2760/14134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2710/10043

  viral genome or elements thereof as genetic vector · CPC title

• C12N2760/14034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2710/10034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title